📣 VC round data is live. Check it out!

Zentalis Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Zentalis Pharma and similar public comparables like Santhera Pharma, IMBiologics, Prelude Therapeutics, Oryzon Genomics and more.

Zentalis Pharma Overview

About Zentalis Pharma

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.


Founded

2014

HQ

United States

Employees

166

Financials (LTM)

Revenue: -
EBITDA: ($159M)

EV

$104M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Zentalis Pharma Financials

Zentalis Pharma reported last 12-month revenue of - and negative EBITDA of ($159M).

In the same LTM period, Zentalis Pharma generated - in gross profit, ($159M) in EBITDA losses, and had net loss of ($143M).

Revenue (LTM)


Zentalis Pharma P&L

In the most recent fiscal year, Zentalis Pharma reported revenue of - and EBITDA of ($144M).

Zentalis Pharma is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Zentalis Pharma
LTMLast FY202320242025202620272028
Revenue---$67M-
EBITDA($159M)($144M)($253M)($186M)($144M)
EBITDA Margin---(276%)-
EBIT Margin---(278%)-
Net Profit($143M)($137M)($292M)($166M)($137M)
Net Margin---(246%)-

Financial data powered by Morningstar, Inc.

Zentalis Pharma Stock Performance

Zentalis Pharma has current market cap of $281M, and enterprise value of $104M.

Market Cap Evolution


Zentalis Pharma's stock price is $3.95.

Zentalis Pharma share price decreased by 1.3% in the last 30 days, and increased by 241.4% in the last year.

Zentalis Pharma has an EPS (earnings per share) of $-1.93.

See more trading valuation data for Zentalis Pharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$104M$281M-0.9%-1.3%68.8%241.4%$-1.93

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Zentalis Pharma Valuation Multiples

Zentalis Pharma trades at (0.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Zentalis Pharma

EV / Revenue (LTM)


Zentalis Pharma Financial Valuation Multiples

As of June 4, 2026, Zentalis Pharma has market cap of $281M and EV of $104M.

Zentalis Pharma has a P/E ratio of (2.0x).

LTMLast FY202320242025202620272028
EV/Revenue---1.5x-
EV/EBITDA(0.7x)(0.7x)(0.4x)(0.6x)(0.7x)
EV/EBIT(0.7x)(0.7x)(0.4x)(0.6x)(0.7x)
P/E(2.0x)(2.1x)(1.0x)(1.7x)(2.1x)
EV/FCF-(0.8x)(0.5x)(0.6x)(0.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Zentalis Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Zentalis Pharma Margins & Growth Rates

Zentalis Pharma grew EBITDA by 18% in the last fiscal year.

See estimated margins and future growth rates for Zentalis Pharma

Zentalis Pharma Margins

2024202720282029
EBITDA Margin(276%)
EBIT Margin(278%)
Net Margin(246%)
FCF Margin(254%)

Zentalis Pharma Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth--(100%)-
EBITDA Growth18%(26%)(23%)18%
EBIT Growth12%(26%)(23%)12%
Net Profit Growth10%(43%)(17%)10%
FCF Growth-(18%)(27%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Zentalis Pharma Operational KPIs

Zentalis Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.

Access forward-looking KPIs for Zentalis Pharma
Last FY2024202620272028
Revenue per Employee$0.0M-
Opex per Employee$0.9M-
G&A Expenses to Revenue-129%
R&D Expenses to Revenue-249%
Opex to Revenue-378%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Zentalis Pharma Competitors

Zentalis Pharma competitors include Santhera Pharma, IMBiologics, Prelude Therapeutics, Oryzon Genomics, Immuneering, Panacea Biotec, Organogenesis, Eledon Pharmaceuticals, Armata Pharmaceuticals and Egetis Therapeutics.

Most Zentalis Pharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Santhera Pharma3.2x2.9x(7.8x)(11.9x)
IMBiologics-27.6x--
Prelude Therapeutics17.8x11.3x(2.1x)(2.0x)
Oryzon Genomics-78.6x(44.4x)(25.5x)
Immuneering--(2.1x)-
Panacea Biotec3.9x-79.5x-
Organogenesis0.7x0.9x4.1x17.7x
Eledon Pharmaceuticals--(2.0x)-

This data is available for Pro users. Sign up to see all Zentalis Pharma competitors and their valuation data.

Start Free Trial

Zentalis Pharma VC Funding History

Before going public, Zentalis Pharma raised $263M in total equity funding, across 3 rounds.


Zentalis Pharma Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-20Undisclosed stage-$144M--
Dec-19Series CEventide; Matrix Capital; Perceptive Advisors; Redmile Group; Surveyor Capital; Viking Global Investors$85M-Zentalis Pharmaceuticals emerged from stealth in September 2019 with an $85 million Series C financing round led by investors including Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Citadel's Surveyor Capital, and Eventide Asset Management. The funding brought the company's total capital raised to $147 million and was intended to advance its solid tumor programs into pivotal clinical trials, broaden the scope of its clinical programs, and support pipeline expansion. At the time, Zentalis had been operating under the radar for five years since its founding, deliberately delaying public emergence to ensure more mature science beyond early-stage projects. The company's lead programs targeted solid tumors, including ZN-c3 (WEE1 kinase inhibitor), an EGFR inhibitor for lung cancer, and a BCL-2 inhibitor (ZN-d5) for blood cancers planned for clinical entry by mid-2020. Its preclinical pipeline included additional programs for blood cancers and solid tumors. CEO Anthony Sun, formerly a partner at Aisling Capital, emphasized advancing to more mature stages with potential combination therapies. Zentalis had outgrown its initial science center and anticipated reaching nearly 100 employees the following year.
Dec-17Series BMatrix Capital; Viking Global Investors$34M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Zentalis Pharma

When was Zentalis Pharma founded?Zentalis Pharma was founded in 2014.
Where is Zentalis Pharma headquartered?Zentalis Pharma is headquartered in United States.
How many employees does Zentalis Pharma have?As of today, Zentalis Pharma has over 166 employees.
Who is the CEO of Zentalis Pharma?Zentalis Pharma's CEO is Julie M. Eastland.
Is Zentalis Pharma publicly listed?Yes, Zentalis Pharma is a public company listed on Nasdaq.
What is the stock symbol of Zentalis Pharma?Zentalis Pharma trades under ZNTL ticker.
When did Zentalis Pharma go public?Zentalis Pharma went public in 2020.
Who are competitors of Zentalis Pharma?Zentalis Pharma main competitors include Santhera Pharma, IMBiologics, Prelude Therapeutics, Oryzon Genomics, Immuneering, Panacea Biotec, Organogenesis, Eledon Pharmaceuticals, Armata Pharmaceuticals, Egetis Therapeutics.
What is the current market cap of Zentalis Pharma?Zentalis Pharma's current market cap is $281M.
Is Zentalis Pharma profitable?No, Zentalis Pharma is not profitable.
What is the current EBITDA of Zentalis Pharma?Zentalis Pharma has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of Zentalis Pharma?Current EBITDA multiple of Zentalis Pharma is (0.7x).
How many companies Zentalis Pharma has acquired to date?Zentalis Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Zentalis Pharma has invested to date?Zentalis Pharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Zentalis Pharma

Lists including Zentalis Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial